BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

enGene, Inc. CSO to Present Key Pre-Clinical Data on EG-10 for Treating Inflammatory Bowel Disease


12/6/2010 11:28:13 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 06, 2010) - enGene Inc., a privately held biotechnology company developing an innovative platform technology to deliver nucleotides (DNA or siRNA) to mucosal tissue for treating a variety of diseases, announced today that Dr. Anthony Cheung, co-founder and Chief Scientific Officer, will give an oral presentation on the Company's compelling pre-clinical data on inflammatory bowel disease (IBD) at the 2010 Advances in IBD - Crohn's & Colitis Foundation's Clinical & Research Conference, being held on December 9-12, 2010 at the Westin Diplomat Hotel in Hollywood, FL.

Dr. Cheung's presentation, entitled, "Successful treatment of experimental colitis by a nanoparticle gene delivery system that localizes expression of interleukin-10 (IL-10) to the colon", will take place at 9:25am, December 11th during the Adaptive Immunity in IBD session.

"The role of IL-10 as a potent anti-inflammatory agent has been well documented in both animal models and human studies," said Dr. Scott Plevy, Assoc. Prof. of Medicine, Microbiology and Immunology at the U. of North Carolina School of Medicine and co-author of the abstract. "A major challenge has always been in the effective delivery of IL-10 - focusing its concentration at the site of disease and minimizing its circulation throughout the body. With this in mind, enGene's technology holds significant promise as a treatment for IBD as well as other gastrointestinal diseases."

More about enGene

enGene Inc. has developed a highly flexible, biopolymer-based nucleotide (DNA and siRNA) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The two lead programs are the localized delivery of an anti-inflammatory cytokine, IL-10, for treating Inflammatory Bowel Disease and delivery of insulin in a physiologic, meal-dependent fashion to regulate blood glucose levels. For more information please visit www.engeneinc.com.


Contacts:
enGene Inc.
Eric A. Adams
President and CEO
604.221.4362
604.221.4369 (FAX)
info@engeneinc.com
www.engeneinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES